Get the Stockscreener App
33.76
6.26%
1.99
After Hours:
33.40
-0.36
-1.07%
Guardant Health Inc stock is traded at $33.76, with a volume of 1.66M.
It is up +6.26% in the last 24 hours and down -5.65% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$31.77
Open:
$32.06
24h Volume:
1.66M
Relative Volume:
0.98
Market Cap:
$4.17B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-7.9623
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+10.91%
1M Performance:
-5.65%
6M Performance:
+18.83%
1Y Performance:
+33.02%
1-Day Range:
$31.72
$33.82
1-Week Range:
$29.91
$33.82
52-Week Range:
$15.81
$38.53
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
33.76 | 4.17B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
532.02 | 203.50B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
234.84 | 169.62B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
135.69 | 38.75B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.39 | 35.83B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
415.53 | 34.03B | 3.84B | 866.24M | 792.60M | 10.37 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Piper Sandler maintains Overweight on Guardant Health stock By Investing.com - Investing.com UK
GHGuardant Health, Inc. Latest Stock News & Market Updates - StockTitan
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Guardant Health, Inc. (NASDAQ:GH) Sees Large Decline in Short Interest - MarketBeat
Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching - Simply Wall St
Natera: Poised For A Great Future But I'd Wait For A Pullback (NASDAQ:NTRA) - Seeking Alpha
Sheffield United takeover completed by COH Sports - Reuters
FDA approves blood-based test screens for colon cancer - MSN
Geode Capital Management LLC Purchases 29,686 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health director Tariq Musa sells $4,042 in common stock - Investing.com India
Guardant Health Partners with MiBA to Transform Cancer Care with AI-Powered Precision Oncology - StockTitan
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Franklin Resources Inc. - MarketBeat
Guardant Health director Tariq Musa sells $4,042 in common stock By Investing.com - Investing.com South Africa
Meaningful Insights Biotech Analytics and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care - Marketscreener.com
Guardant Health and COTA partner in advanced oncology R&D - TipRanks
Guardant Health Partners with COTA to Revolutionize Cancer Drug Development Through AI-Powered Data - StockTitan
Y Intercept Hong Kong Ltd Sells 38,937 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health teams up with Boehringer for cancer test By Investing.com - Investing.com Australia
Guardant Health teams up with Boehringer for cancer test - Investing.com
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer - Business Wire
Guardant Health Partners with Boehringer Ingelheim on Breakthrough Lung Cancer Diagnostic Test - StockTitan
Insider Selling: Guardant Health, Inc. (NASDAQ:GH) Director Sells 2,320 Shares of Stock - MarketBeat
Guardant Health director Tariq Musa sells $81,200 in stock - Investing.com
681,074 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Lord Abbett & CO. LLC - MarketBeat
XTX Topco Ltd Has $409,000 Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Receives $40.60 Consensus Target Price from Analysts - MarketBeat
(GH) Trading Report - Stock Traders Daily
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal - The Eastern Progress Online
Verition Fund Management LLC Buys 25,900 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium - The Bakersfield Californian
Wellington Management Group LLP Purchases 6,618,785 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health to Showcase Breakthrough Liquid Biopsy Research at Major Breast Cancer Symposium - StockTitan
Pier Capital LLC Buys 42,575 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Shares Bought by Two Sigma Advisers LP - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Temasek Holdings Private Ltd Reduces Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Charles Schwab Investment Management Inc. Has $23.01 Million Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Investors in Guardant Health (NASDAQ:GH) from three years ago are still down 61%, even after 8.6% gain this past week - Yahoo Finance
Strong week for Guardant Health (NASDAQ:GH) shareholders doesn't alleviate pain of three-year loss - Simply Wall St
Guardant Health stock soars to 52-week high of $37.04 By Investing.com - Investing.com Nigeria
Guardant Health Inc (GH) Shares Up 4.11% on Dec 4 - GuruFocus.com
Guardant Health stock soars to 52-week high of $37.04 - Investing.com
Guardant Health Stock Flashing Surefire ‘Buy’ Signal - Forbes
The Manufacturers Life Insurance Company Sells 28,746 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (FRA:5GH) Shares Outstanding (EOP) : 123.2 Mil (As of Sep. 2024) - GuruFocus.com
Liquid Biopsy Market Is Booming So Rapidly with Major Giants - openPR
Guardant awarded nearly $293M in false ad trial against Natera - MedTech Dive
Erste Asset Management GmbH Buys New Stake in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Fred Alger Management LLC Sells 43,039 Shares of Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
GH (Guardant Health) EBITDA per Share : $-3.86 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health (STU:5GH) EPS (Diluted) : €-3.89 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kalia Kumud | Chief Information Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
2,690 |
0 |
21,098 |
| Freeman Chris | Chief Commercial Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
3,595 |
0 |
35,852 |
| EAGLE CRAIG | Chief Medical Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
3,381 |
0 |
27,343 |
| Chudova Darya | Chief Technology Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
3,006 |
0 |
57,786 |
| Bell Michael Brian | Chief Financial Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
2,084 |
0 |
27,772 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
11,462 |
0 |
2,215,894 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
94,555 |
0 |
2,304,640 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
11,462 |
0 |
2,315,728 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Jan 01 '25 |
Option Exercise |
0.00 |
94,555 |
0 |
2,404,474 |
| Krognes Steve E. | Director |
Dec 31 '24 |
Option Exercise |
0.00 |
155 |
0 |
10,220 |
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):